drugset / Trial / NCT01734447

Long Term Effect of Somatropin in Subjects With Intrauterine Growth Retardation

NCT01734447

Phase 4 Completed 57 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to assess the safety of long-term growth hormone treatment in growth-retarded children with intrauterine growth retardation (IUGR) enrolled in trial GHRETARD/F/1/F.

Timeline

Start
2000-04-30
Primary completion
2003-04-30
Completion
2003-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic 1.2 iu/kg
Subject Somatropin Protein / enzyme biologic 2.4 iu/kg